Chronos announces positive pre-clinical results for the lead compound in its DAT inhibitor programme in an in vivo model of fatigue in multiple sclerosis (MS). Read the press release.
Chronos has demonstrated positive pre-clinical proof of concept (POC) results for the lead compound in its orexin-1 antagonist programme in an in vivo model of binge eating disorder (BED). Read [...]
A patent application for our novel orexin 1 antagonist has been filed on 1 September 2017. This is an entirely new composition of matter patent supporting our binge eating disorder and alcohol [...]
Chronos announces a major partnership with Aptuit Verona, Italy for specific orexin 1 antagonist programme. Read the press release.